(Fulton, 11/9) In other pharmaceutical news — Reuters: Eli Lilly Ordered To Pay $176.5 Mln To Teva In U.S. Migraine Drug Patent Trial Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday. The jury agreed with Teva that Lilly's Emgality violated its rights in the patents, which relate to its own migraine drug Ajovy. Both drugs treat migraines by employing antibodies to inhibit headache-causing peptides. (Brittain, 11/9) Stat: Clovis Oncology Warns Of Likely Bankruptcy Filing Clovis Oncology, a maker of cancer drugs, warned Wednesday that it will likely file for bankruptcy protection due to dwindling sales of its sole product, mounting financial losses, and a crushing debt load.